Chemclin Diagnostics Co., Ltd. (“Chemclin Diagnostics”, Stock Code: 688468.SH) completed its IPO of A shares and listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange (SSE STAR Market) on April 9, 2021, offering 41 million RMB-denominated common shares and raising a total of approximately RMB 293 million.

Chemclin Diagnostics is a high-tech enterprise mainly engaged in the R&D, production and sales of chemiluminescent diagnostic reagents and instruments for clinical immunology. The company's products include LiCA diagnostic reagents based on the Light Initiated Chemiluminescent Assay, and CC diagnostic reagents and instruments based on the Chemiluminescence Enzyme Immunoassay, which are used to detect markers of infectious diseases (e.g., hepatitis B, hepatitis C, AIDS, syphilis, hepatitis A and hepatitis E), tumor markers, thyroid hormone, reproductive endocrine hormone, cardiac markers and inflammations. 

Chemclin Diagnostics is the first enterprise to develop the chemiluminescent technology based on the "homogeneous chemiluminescence assay of reactive oxygen species" and realize its industrialization in China. After years of research and exploration, the company has established its light initiated chemiluminescent technology platform with independent intellectual property rights, developed nearly 50 liCA reagents applied to the clinical detection of infectious diseases, tumor markers, thyroid hormone, reproductive endocrine hormone, cardiac markers and inflammations, and been close to world top brands in terms of the number of detection items.

As the legal adviser to the issuer, Jingtian & Gongcheng's legal team provided one-stop, end-to-end and multi-dimensional legal services to Chemclin Diagnostics. The team was highly recognized by the client and other intermediaries for the strict work attitude, as well as efficient and timely legal services.